NEW SITE — FASTER TURNAROUND, MORE LABS. READ ON
Free peptide testing

Ordered peptides from Kerui Peptide HongKong? Mail in a sample (US only) and let us test it.

Test my supply
+10 more ↓
63%
Finnrick rating
#367 of 457 ranked vendors
23 of 34 classifiable tests passed
methodology · Purity focus
Finnrick analysis

Kerui Peptide HongKong's purity-focus record is narrow but includes intermittent strong Retatrutide results, with recent 99.9% purity passes showing some high-end performance. The same Retatrutide evidence is volatile and failure-heavy, including identity/0 mg results and an 85.9% purity sample, so confidence is constrained by dispersion despite recency.

methodology →
vendor intelligence report
Vendor Intelligence Report: Kerui Peptide HongKong

A live Hong Kong company record is real, but WHOIS, hosting paths, and forum placement point away from a simple Hong Kong operating story. The report maps the Emily-KR/Iris1 sales trail, payment rails, and GLP-1 enforcement exposure.

22 pages5 risk factors assessed2 Jul 2026
read the report
Peptides
#
Peptide
$/MG
Rating
N
1
GHK-Cu
$0.07
89%
4
2
Tirzepatide
$0.54
79%
5
3
Retatrutide
$0.64
73%
16
4
BPC-157
$0.66
54%
2
5
Tesamorelin
$1.70
50%
3
6
NAD+
$0.01
20%
4
7
5-Amino-1MQ
$0.17
-
0
8
Cagrilintide
$2.72
-
0
9
CJC-1295
$2.38
-
0
11
GLOW
$0.29
-
0
12
Glutathione
$0.01
-
0
13
Ipamorelin
$0.74
-
0
14
KLOW
$0.23
-
0
15
KPV
$0.54
-
0
16
MOTS-c
$0.53
-
0
Contact channels
Rating trend
CUMULATIVE FINNRICK RATING
83%+65%+48%+30%+<30%3 Jul 2025: 63%29 Jan 2026: 74%2 Feb 2026: 81%8 May 2026: 71%8 May 2026: 66%20 May 2026: 69%20 May 2026: 70%20 May 2026: 69%20 May 2026: 68%28 May 2026: 69%2 Jun 2026: 68%4 Jun 2026: 64%17 Jun 2026: 64%10 Jul 2026: 64%13 Jul 2026: 62%22 Jul 2026: 62%3 Aug 2026: 62%3 Aug 2026: 62%3 Aug 2026: 62%5 Aug 2026: 62%5 Aug 2026: 63%13 Aug 2026: 63%15 Aug 2026: 63%15 Aug 2026: 64%26 Aug 2026: 64%28 Aug 2026: 63%10 Sep 2026: 62%15 Sep 2026: 62%15 Sep 2026: 63%17 Sep 2026: 63%17 Sep 2026: 62%18 Sep 2026: 62%19 Sep 2026: 62%20 Sep 2026: 63%7 Oct 2026: current 63%63%74%63%Jul 25Oct 26
Free peptide testing

Ordered peptides from Kerui Peptide HongKong? Mail in a sample (US only) and let us test it.

Test my supply
Kerui Peptide HongKong test history
COA-backed lab tests
DateResultTestLabPurityDosageLabelCOA
20 Sep 2026
Pass
Retatrutide
lab nameView COA
19 Sep 2026
Pass
GHK-Cu
lab nameView COA
18 Sep 2026
Pass
Retatrutide
lab nameView COA
17 Sep 2026
Pass
GHK-Cu
lab nameView COA
17 Sep 2026
Fail
NAD+
lab nameView COA
15 Sep 2026
Pass
Retatrutide
lab nameView COA
15 Sep 2026
Pass
GHK-Cu
lab nameView COA
10 Sep 2026
Fail
Tirzepatide
lab nameView COA
28 Aug 2026
Fail
Retatrutide
lab nameView COA
26 Aug 2026
Pass
Retatrutide
lab nameView COA
1-10 of 34

About Kerui Peptide HongKong test results from Finnrick

Kerui Peptide HongKong is a peptide vendor tracked in Finnrick's independent testing dataset. This page compiles batch-level results across 6 peptides and 34 tests, including ratings, observed price signals, recent test dates, and correction history where available.

Finnrick ratings are calculated from published sample data using the selected rating standard. The default standard evaluates purity, dose accuracy, and label quality, then adjusts low-volume results so small sample counts do not appear more certain than the data supports.

The most visible Kerui Peptide HongKong peptides in this dataset are BPC-157 (2 tests), GHK-Cu (4 tests) and NAD+ (4 tests). Use the peptide table above to compare the current Finnrick rating, price per mg, and sample volume for each peptide.

Recent tests and corrections are shown below when available. Samples may be acquired by Finnrick directly or submitted through Finnrick testing programs; the goal is to make safety and supply-chain evidence easier to evaluate than vendor marketing claims alone. This page currently lists 34 recent tests.

Corrections
No corrections.
Free peptide testing

Ordered peptides from Kerui Peptide HongKong? Mail in a sample (US only) and let us test it.

Test my supply